कंपनी का अवलोकन
RedHill Biopharma Ltd. operates as a specialty biopharmaceutical entity dedicated to developing and commercializing therapeutic solutions specifically for gastrointestinal and infectious diseases. The company's primary commercial focus includes the development of Talicia for the management of H. pylori infections in adult populations, alongside the commercialization of Aemcolo designed to treat travelers' diarrhea in adults. This organization functions within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas rather than mass-market pharmaceuticals. The company currently maintains a market capitalization of $4.09M and generates annual revenue of $9.55M, supported by a workforce of 35 employees. These valuation and revenue figures indicate that RedHill Biopharma Ltd. occupies a small-cap position within the pharmaceutical landscape, reflecting a stage where limited scale and a specialized product pipeline are defining its current financial footprint.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $9.55M, yet simultaneously posted a net income of $-9,313,000 and an EBITDA of $-8,336,000. The substantial disparity between the positive revenue of $9.55M and the significant negative net income of $-9,313,000 reveals a cost structure characterized by high operational expenses that currently outweigh all income streams. Free cash flow stands at $-4,080,000, which indicates that the company is burning cash to fund its research and development activities rather than generating liquidity for immediate operational needs. This negative free cash flow position suggests limited financial flexibility, requiring the company to rely on existing cash reserves or external financing to sustain operations. Margin analysis shows a Gross Margin of 64.4%, indicating efficient production costs relative to sales, while the Operating Margin of -107.3% and Profit Margin of -97.5% highlight severe operational inefficiencies or high research expenditures eroding profitability. On the balance sheet, the company holds $2.87M in cash against a debt load of $214,000, and since the Debt to Equity ratio is listed as N/A, the leverage profile is difficult to quantify using standard metrics but appears relatively low in absolute debt terms. However, the Current Ratio of 0.56 signals potential short-term liquidity constraints, as current liabilities exceed current assets, suggesting the company may struggle to meet obligations due within one year without refinancing or additional funding. Furthermore, the Return on Equity is N/A and the Return on Assets is -25.3%, metrics that collectively reveal management is currently unable to generate positive returns on shareholder capital or the total asset base due to persistent losses.
मूल्यांकन आकलन
Valuation metrics present a complex picture where the P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is 26.66, implying market expectations of future profitability that have not yet materialized in trailing figures. The Price to Book ratio stands at -0.33, indicating that the market values the company at a fraction of its book value, a common characteristic for distressed or pre-profitability biotechnology firms. The Price to Sales ratio is 0.43, suggesting the market is valuing the company at less than half its revenue, while the EV/EBITDA of -1729.79 further underscores the lack of current earnings power relative to enterprise value. Regarding price volatility, the stock has traded between a 52-Week High of $3.31 and a 52-Week Low of $0.71, and without a specific current price provided in the facts, the valuation is best understood through these historical bounds which define the risk-reward spectrum. The Beta of 4.92 indicates extreme sensitivity to market movements, meaning the stock's price volatility is nearly five times that of the broader market, reflecting the high-risk nature of investing in a small-cap biopharmaceutical company with limited revenue history.
Growth & Income
The company demonstrates robust top-line expansion with a Revenue Growth (YoY) of 58.6%, whereas Earnings Growth (YoY) is N/A, indicating that earnings are not currently growing alongside revenue due to persistent losses. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning all available cash is directed back into the business for growth initiatives rather than distributed to shareholders. The absence of a dividend payout ratio eliminates concerns regarding sustainability issues, as the company reinvests its limited earnings and cash reserves directly into the development of its gastrointestinal and infectious disease pipeline. In summary, RedHill Biopharma Ltd. exhibits a growth-oriented profile driven by significant revenue acceleration but lacks income generation capabilities, prioritizing pipeline advancement over shareholder returns.